SOTIO Exercises Second Target Option in Existing Collaboration with NBE-Therapeutics to Develop Next Generation Antibody-Drug Conjugates

Madeira Public Health Service SESARAM EPERAM collaborates with the EU | mifuturonorcal

Basel, Switzerland and Prague, Czech Republic – November 7, 2019 – NBE-Therapeutics AG and SOTIO today announced that SOTIO has selected a second target for the development of a next generation antibody-drug conjugate (ADC) based on their existing collaboration and license agreement. NBE and SOTIO will collaborate on the discovery, non-clinical development and manufacturing of this undisclosed second target. Development will be based on NBE’s proprietary antibody drug conjugate platform, including NBE’s SMAC-technology™ site-specific conjugation and its powerful new anthracycline toxin platforms. SOTIO will assume global responsibility for the clinical development, registration and commercialization of ADC products.

NBE-Therapeutics’ new iADC™ platform creates highly potent and safe immunostimulatory ADCs with anthracycline payload, inducing a long-lasting antitumor immunological effect. It showed unprecedented preclinical data on efficacy, as well as safety, across multiple pipeline programs. Its lead program NBE-002 against the ROR1 target has successfully passed the GLP toxicology study and is in the final stages of the CMC. It is expected to begin its first human study by mid-2020 for triple-negative breast cancer and lung cancer, as well as other cancer indications.

NBE is entitled to the option exercise fee, as well as milestone payments and royalties based on the overall net sales of the products. In addition, NBE will be reimbursed for R&D expenses incurred in connection with product development in collaboration with SOTIO.

Dr. Ulf Grawunder, CEO of NBE-Therapeutics, commented: “We are very excited that SOTIO has nominated a second ADC program under the existing collaboration agreement between SOTIO and NBE, confirming the high quality of our platform adc. We have now created a robust and scalable ADC platform that allows us to leverage iADC development in clinical trials for more programs. Collaborating with Sotio in recent years has further strengthened our technology and we are very proud to have them on board for a second iADC development program.”

« Based on the very encouraging data from our first NBE collaboration target and SO-N102 program, as well as data from NBE’s proprietary program NBE-002, we have now exercised the second target option in the collaboration, » says Dr. Radek Spisek, CEO of SOTIO. « NBE’s product platform addresses key issues of today’s antibody-drug conjugates and has the potential to provide new and superior therapeutic options for cancer patients. »

About NBE-Therapeutics
NBE-Therapeutics is a privately owned Swiss biotechnology company headquartered in Basel, founded in 2012 with the goal of developing next-generation immune-stimulating antibody drug conjugate (iADC™) products. NBE takes its products to clinical proof of concept with the aim of improving treatment options for cancer patients. The company leverages proprietary platforms covering all aspects of ADC development: its Transpo-mAb Display™ technology for antibody discovery, its SMAC-Technology™ for site-specific conjugation of toxin payload with antibodies and a new highly effective and immunostimulating anthracycline-based toxin platform. The company is financially backed by Boehringer Ingelheim Venture Fund (D), PPF Group and Novo Holdings (DK) as institutional investors, and other private investors from Switzerland, Germany and the Netherlands. For more information on NBE visit the website www.nbe-therapeutics.com.

About SOTIO
SOTIO is an international biotechnology company leading PPF Group’s efforts to build a diversified biotechnology portfolio through its own research and development, collaborations, licensing, investments, mergers and acquisitions. The company is developing new medical therapies, focusing on the treatment of cancer. The most advanced project is its proprietary active cell immunotherapy platform based on dendritic cells. SOTIO is testing the safety and efficacy of its DCVAC products through multiple Phase I and Phase III clinical trials. One of its affiliates, Cytune Pharma, a French biotech company focusing on the development of new immunotherapies for the treatment of cancer, is currently evaluating its SO-C101 (IL-15-based) lead program in Phase I clinical trial in collaboration with SOTIO. SOTIO is also looking to partner with other companies and institutions developing promising cancer therapies. SOTIO has facilities in Europe, the United States, China and Russia and has all the necessary functionality in-house for research, clinical development and market access. For more information about the company visit the website www.sotio.com.

-END-

Media Inquiries
Ulf Grawunder
CEO, NBE Therapeutics AG
T: +41 61 633 2230
E: ulf.grawunder@nbe-therapeutics.com